Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1385 participants.
Also called NCT04518293
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,385 participants
- Sponsor
- George Medicines PTY Limited
- Registry
-
NCT04518293
-
- Other papers using this trial's data
- Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Czechia, New Zealand, Poland, Sri Lanka, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04518293. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-09 (actual); primary completion 2023-08-11 (actual). Results posted on 2025-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
- Acronym
- GMRx2_ACT
- Condition
- Hypertension
- Intervention (Drug)
- Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Intervention (Drug)
- telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
- Intervention (Drug)
- Telmisartan 20 mg/amlodipine 2.5 mg
- Intervention (Drug)
- telmisartan 40 mg/amlodipine 5 mg
- Intervention (Drug)
- Telmisartan 20 mg/indapamide 1.25 mg
- Intervention (Drug)
- telmisartan 40 mg/indapamide 2.5 mg
- Intervention (Drug)
- Amlodipine 2.5 mg/indapamide 1.25 mg
- Intervention (Drug)
- amlodipine 5 mg/indapamide 2.5 mg
- Lead sponsor
- George Medicines PTY Limited
Record details
- Record id
cardio:ct-nct04518293- Content hash
0513b47ea4b70389daf379fdb4a63ebef536ca91396e57b70f81f40a50c0388d